Benzinga | Oct 20, 2020 06:03AM EDT

CENTOGENE Announces CEO Transition

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that Prof. Arndt Rolfs, the Company's Chief Executive Officer (CEO) and founder, has decided to step down as CEO of CENTOGENE as of October 20, 2020, and that Andrin Oswald, M.D., will join the Company as CEO on December 1, 2020. Prof. Rolfs has agreed to serve as an advisor during the transition period.